pyrroles has been researched along with Vasculitis in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (8.33) | 18.2507 |
2000's | 7 (58.33) | 29.6817 |
2010's | 3 (25.00) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
Authors | Studies |
---|---|
Hayashi, S; Itoh, I; Iwano, M; Kasuno, K; Kimura, H; Ojima, T; Shimizu, H; Takahashi, N; Yamamoto, C | 1 |
Devlin, J; Haroon, M | 1 |
Anthony, FW; Curzen, NP; Hanson, MA; Hopkins, LA; Kelsall, CJ; Torrens, C | 1 |
Chen, YX; Fu, Y; Kong, MY; Nie, RQ; Wang, JF; Wang, XQ; Yao, YJ | 1 |
Hirata, Y; Sata, M | 1 |
Li, JJ | 1 |
Adachi, M; Gushiken, N; Hirano, T; Hyodo, T; Ikejiri, A; Murayama, S; Taira, T; Yoshino, G | 1 |
Apperson-Hansen, C; Churchill, T; Crowe, T; Lin, S; Loyd, A; Magyar, WA; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wang, C; Wolski, K | 1 |
Sparks, DL; Stankovic, G | 1 |
Jankl, S; Kofler, S; Nickel, T; Schlichting, C; Weis, M | 1 |
Auteri, A; Capati, E; Puccetti, L | 1 |
Goto, S; Kitagaki, K; Koda, A; Nagai, H; Suda, H | 1 |
2 trial(s) available for pyrroles and Vasculitis
Article | Year |
---|---|
Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
Topics: Adaptation, Physiological; Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Models, Cardiovascular; Pravastatin; Prospective Studies; Pyrroles; Risk Factors; Single-Blind Method; Triglycerides; Ultrasonography, Interventional; Vasculitis | 2006 |
Change in circulating C-reactive protein is not associated with atorvastatin treatment in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cognition; Coronary Artery Disease; Heptanoic Acids; Humans; Middle Aged; Neuropsychological Tests; Placebos; Prognosis; Pyrroles; Vasculitis | 2006 |
10 other study(ies) available for pyrroles and Vasculitis
Article | Year |
---|---|
IgA Vasculitis Developed as an Adverse Effect of Tofacitinib Taken for Rheumatoid Arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunoglobulin A; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha; Vasculitis | 2020 |
A case of ANCA-associated systemic vasculitis induced by atorvastatin.
Topics: Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Anticholesteremic Agents; Atorvastatin; Azathioprine; Heptanoic Acids; Humans; Immunosuppressive Agents; Male; Methylprednisolone; Middle Aged; Pyrroles; Vasculitis | 2008 |
Atorvastatin restores endothelial function in offspring of protein-restricted rats in a cholesterol-independent manner.
Topics: Animals; Atorvastatin; Cholesterol; Disease Models, Animal; Endothelium, Vascular; Female; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Nitric Oxide Synthase Type III; Oxidative Stress; Pregnancy; Prenatal Exposure Delayed Effects; Protein-Energy Malnutrition; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Vasculitis; Vasoconstriction; Weight Gain | 2009 |
Pivotal role of inflammation in vascular endothelial dysfunction of hyperlipidemic rabbit and effects by atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Dietary Fats; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hyperlipidemias; Insulin; Lipids; Male; Pyrroles; Rabbits; Vasculitis | 2011 |
Synergistic protection against vascular inflammation with a calcium channel blocker and a statin.
Topics: Amlodipine; Animals; Atorvastatin; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Femoral Artery; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Mice; Pyrroles; Vasculitis | 2011 |
Inflammatory rebound phenomenon after abrupt withdrawal of statin is a mature point of view but not hypotheses.
Topics: Animals; Authorship; Heptanoic Acids; Humans; Hyperlipidemias; Male; Publishing; Pyrroles; Vasculitis | 2011 |
Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.
Topics: Alanine Transaminase; Apolipoproteins B; Aspartate Aminotransferases; Atorvastatin; C-Reactive Protein; Cholesterol; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Particle Size; Pyrroles; Renal Dialysis; Triglycerides; Vasculitis | 2004 |
Dual mode of HMG-CoA reductase inhibition on dendritic cell invasion.
Topics: Antibodies; Atherosclerosis; Atorvastatin; Cell Adhesion; Cell Line; Cell Movement; Cholesterol; Dendritic Cells; Dose-Response Relationship, Drug; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prenylation; Pyrroles; Vasculitis | 2008 |
Genetic modulation of anti-inflammatory effects of atorvastatin; probably a multi-gene condition.
Topics: Anti-Inflammatory Agents; Atorvastatin; Heptanoic Acids; Humans; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrroles; Vasculitis | 2008 |
Effect of three novel K+ channel openers, cromakalim, pinacidil and nicorandil on allergic reaction and experimental asthma.
Topics: Airway Resistance; Animals; Asthma; Benzopyrans; Bronchodilator Agents; Cromakalim; Guanidines; Guinea Pigs; In Vitro Techniques; Mice; Mice, Inbred Strains; Niacinamide; Nicorandil; Passive Cutaneous Anaphylaxis; Pinacidil; Potassium Channels; Pyrroles; Rats; Trachea; Vasculitis | 1991 |